These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30528089)

  • 1. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
    Ou L; DeKelver RC; Rohde M; Tom S; Radeke R; St Martin SJ; Santiago Y; Sproul S; Przybilla MJ; Koniar BL; Podetz-Pedersen KM; Laoharawee K; Cooksley RD; Meyer KE; Holmes MC; McIvor RS; Wechsler T; Whitley CB
    Mol Ther; 2019 Jan; 27(1):178-187. PubMed ID: 30528089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
    Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
    Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
    Laoharawee K; DeKelver RC; Podetz-Pedersen KM; Rohde M; Sproul S; Nguyen HO; Nguyen T; St Martin SJ; Ou L; Tom S; Radeke R; Meyer KE; Holmes MC; Whitley CB; Wechsler T; McIvor RS
    Mol Ther; 2018 Apr; 26(4):1127-1136. PubMed ID: 29580682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
    Dai M; Han J; El-Amouri SS; Brady RO; Pan D
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
    Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
    Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
    Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
    Ou L; Przybilla MJ; Koniar B; Whitley CB
    Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
    Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
    Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucopolysaccharidoses type I gene therapy.
    Hurt SC; Dickson PI; Curiel DT
    J Inherit Metab Dis; 2021 Sep; 44(5):1088-1098. PubMed ID: 34189746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
    Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
    Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
    Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.
    de Carvalho TG; Schuh R; Pasqualim G; Pellenz FM; Filippi-Chiela EC; Giugliani R; Baldo G; Matte U
    Gene; 2018 Dec; 678():33-37. PubMed ID: 30081189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo adenine base editing corrects newborn murine model of Hurler syndrome.
    Su J; Jin X; She K; Liu Y; Song L; Zhao Q; Xiao J; Li R; Deng H; Lu F; Yang Y
    Mol Biomed; 2023 Feb; 4(1):6. PubMed ID: 36813914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.